TCR IVT Products

Scientific advancements in adoptive T-cell therapy have revolutionized the treatment landscape for cancer and infectious diseases. Utilizing Chimeric Antigen Receptors (CAR) and T cell Receptors (TCR) has shown promising outcomes in clinical trials. However, the high cost and complexity of in vitro manufacture of engineered T cells poses many challenges. In this context, Creative Biolabs introduces an innovative approach by offering in vitro transcription (IVT) products and services for TCR. Our TCR-IVT products aim to transiently reprogram T cells to target disease-specific antigens, presenting a potentially cost-effective and efficient alternative in adoptive cell therapy.

Fig.1 Schematic diagram of in situ CARs or TCRs engineering using IVT mRNA nanoparticles.¹

TCR-IVT Vector and mRNA Product at Creative Biolabs

Customized TCR-IVT Vector

The TCR-IVT vector system designed by Creative Biolabs is tailored for optimizing mRNA synthesis for a wide range of research applications. Using the T7 promoter upstream of the target sequence, this vector enables efficient mRNA production by T7 phage RNA polymerase. The system is engineered for run-off transcription, ensuring complete transcription of the target sequence. Linearization of the plasmid template is recommended before in vitro transcription to maintain transcript length and sequence integrity.

Customized TCR-IVT mRNA

Our TCR-IVT mRNA products are designed to meet the demands of in vitro translation, biochemical studies, and protein expression upon injection into cells. The inclusion of a 7-methylguanosine cap at the 5' end of mRNA transcripts is crucial for RNA stability and efficient translation, ensuring optimal performance in various applications. At Creative Biolabs, we offer capped RNA synthesis co-transcriptionally using cap analogs or post-transcriptionally via capping enzymes, allowing for the production of functional, capped RNA suitable for therapeutic use.

Our IVT Solution and Services

Creative Biolabs provides a comprehensive platform for TCR-IVT RNA therapeutics, encompassing vaccine development, TCR-T therapy. Our expertise in IVT RNA synthesis and lipid nanoparticle encapsulation enables researchers to accelerate the development of RNA-based expression systems. With customizable IVT RNA production and LNP encapsulation, our team offers in vitro and in vivo candidate screening and functional testing services to support the advancement of RNA therapeutics.

Our state-of-the-art facilities and equipment ensure the highest quality and consistency in RNA production. Quality control assays are performed to validate the purity and integrity of IVT RNA products, guaranteeing optimal performance and efficacy in therapeutic applications. Creative Biolabs' team of scientists possesses extensive experience in therapeutic IVT vector design, sequence optimization, and process development, ensuring that each IVT product meets the highest standards of quality and efficacy.

Fig.2 Diagram of IVT mRNA and LNP production process.

Our Advantages

• Customized TCR-IVT vectors: Our seasoned team of experts can develop personalized TCR-IVT vectors designed to target disease-specific antigens, enhancing the specificity and efficacy of T cell therapy approaches.
• State-of-the-art mRNA and mRNA-LNP products: We employ the latest technologies to generate high-quality in vitro-transcribed mRNA and lipid nanoparticle formulations for efficient T cell reprogramming, promoting therapeutic success and improved patient outcomes.
• Comprehensive IVT solution and services: From vector design and sequence optimization to process development and quality control, our comprehensive IVT solution encompasses every aspect of TCR engineering, ensuring seamless integration and optimized performance.
• Expertise in RNA therapeutics: Leveraging our extensive experience in RNA therapeutics, our dedicated team can provide in vitro transcription RNA synthesis and LNP encapsulation services, facilitating the development of a wide range of RNA-based expression systems with exceptional precision and efficacy.

By choosing Creative Biolabs for your TCR-IVT product and service needs, you gain access to a wealth of expertise, cutting-edge technologies, and customized solutions that are tailored to elevate your research, development, and therapeutic endeavors to new heights of success. Collaborate with us today to unlock the full potential of TCR engineering for cellular therapies.

Reference

1. Parayath, N. N., et al. "In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo." Nature communications 11.1 (2020): 6080.